GlaxoSmithKline

Breast cancer patients invited to drug trials

PUBLISHED : Wednesday, 13 June, 2007, 12:00am
UPDATED : Wednesday, 13 June, 2007, 12:00am

Breast cancer patients are being asked to join two international clinical trials for a drug that has been shown to improve survival. Lapatinib, approved by US and Swiss regulators, blocks the HER2 gene, which causes an aggressive form of the cancer. About 3,500 women will participate in the studies, to find out if the drug can supplement the drug Paclitaxel. The local trials will be conducted by HKU and Unimed Medical Institute.